By FormBlends Editorial Research|Source reviewed by FormBlends Medical Team|| Source Reviewed Written by FormBlends Editorial Research Checked against primary sources by FormBlends Medical Team In This Article This article is part of our Provider Comparisons collection
The bottom line on side effects: Retatrutide is not dramatically riskier for most people, but it is not a simple lateral move
In the SURMOUNT 1 trial, tirzepatide at doses of 5 mg, 10 mg and 15 mg were evaluated against placebo, with pooled tirzepatide groups resulting in significant decreases in total cholesterol, LDL-C, VLDL-C, FFA, and triglycerides and an increase in HDL-C at week 72 of follow-up [35]
Both medications work through the same GLP-1 pathway
When Results Plateau In community-reported reta+cagri protocols, plateaus are commonly reported at: Month 68 for users who hold retatrutide at 2 mg/week typically resolves by titrating retatrutide to 3 mg or holding while cagrilintide finishes ramping to 2.4 mg Month 12+ for users at the community ceiling (reta 4 mg + cagri 2.4 mg) no additional dose lever within the conservative community protocol
When to Adjust Your Tirzepatide Protocol If sulfur burps persist beyond week 4 or become severe enough to affect daily life, contact your PlexusDx clinician